

## The Molecular Steps of Citrinin Biosynthesis in Fungi

Yi He<sup>1,2</sup> and Russell J. Cox<sup>2,3\*</sup>

1. College of Food Science and Technology, Huazhong Agricultural University, Wuhan 430070, Hubei Province, P. R. China.

2. Institut für Organische Chemie, Leibniz Universität Hannover, Schneiderberg 1B, 30167 Hannover, Germany.


3. School of Chemistry, University of Bristol, Cantock's Close, Bristol, BS8 1TS, UK.

\* Corresponding author: russell.cox@oci.uni-hannover.de

### ELECTRONIC SUPPLEMENTARY INFORMATION

1. Annotated Genome Map of Citrinin Biosynthetic Gene Cluster in <i>M. ruber</i>	2
2. Comparision of citrinin biosynthesis gene clusters from <i>M. ruber</i> , <i>M. aurantiacus</i> , <i>M. purpureus</i> and <i>P. expansum</i>	4
3. Investigation of <i>citS</i> intron 2	5
4. Domain analysis of citrinin polyketide synthase (CitS)	7
5. LCMS chromatograms	8
6. LC-HRMS data for compounds 1 - 9	35
7. NMR data for compounds 1 - 9	46
8. Experimental Details	109
9. Previous Biosynthetic Proposals for Citrinin from the Literature	126
10. 3D Model of CitS Reductive Release Domain	129
11. Presumed Mechanism of CitE / mrl6	131
12. References	132


# 1. Gene map and annotation of the 44 kb citrinin gene cluster from *Monascus ruber* M7



Gene	Size (bp/aa)	Plausible function	Protein with high similarity	Similarity at amino acid level (%)	Gene loci in the <i>M. ruber</i> genome
<i>citS</i>	7782/2593	Citrinin polyketide synthase	<i>M. purpureus</i> citrinin PKS (BAD44749.1)	99	GME2757
<i>mrl1</i>	786/261	Serine hydrolase, FSH1	<i>Botryotinia fuckeliana</i> putative citrinin biosynthesis oxydoreductase protein (EMR80654.1)	63	GME2756
<i>mrl2</i>	990/329	2-oxoglutarate (2OG) and Fe(II)-dependent oxygenase	<i>Botryotinia fuckeliana</i> putative 2og-fe oxygenase protein (XP_001559291.1)	69	GME2755
<i>mrl3</i>	1530/509	Transcriptional regulator (GAL4-like Zn(II) <sub>2</sub> Cys <sub>6</sub> )	<i>Metarhizium acridum</i> citrinin biosynthesis transcriptional activator CtnR (EFY89368.1)	50	GME2754
<i>mrl4</i>	1506/501	NAD(P)+ dependent aldehyde dehydrogenase	<i>Metarhizium anisopliae</i> dehydrogenase (EFY95582.1)	58	GME2753
<i>mrl5</i>	390/129	Glyoxalase-like domain	<i>Aspergillus terreus</i> predicted protein (XP_001212470.1)	81	GME2752
<i>mrl6</i>	879/292	Short-chain dehydrogenase	<i>Botryotinia fuckeliana</i> similar to short-chain dehydrogenase/reductase SDR (CCD44944.1)	69	GME2751
<i>mrl7</i>	1869/622	Glucose-methanol-choline oxidoreductase	<i>Botryotinia fuckeliana</i> GMC oxidoreductase (CCD44943.1)	61	GME2750

<i>mrr1</i>	1500/499	Major Facilitator Superfamily (MFS) protein	<i>Aspergillus oryzae</i> MFS multidrug transporter (XP_001822369.1)	64	GME2758
<i>mrr2</i>	828/275	Histidine Phosphatase	<i>Aspergillus niger</i> phosphoglycerate mutase family protein (XP_001394319.1)	74	GME2759
<i>mrr3</i>	1500/499	No putative conserved domains have been detected	<i>Aspergillus oryzae</i> hypothetical protein AOR_1_400154 (XP_001819450.1)	55	GME2760
<i>mrr4</i>	2118/705	WD40 protein	<i>Aspergillus flavus</i> WD repeat protein (XP_002372745.1)	59	GME2761
<i>mrr5</i>	666/221	Carbonic anhydrases	<i>Aspergillus oryzae</i> putative carbonic anhydrase involved in protection against oxidative damage (EIT80876.1)	73	GME2762
<i>mrr6</i>	570/189	No putative conserved domains have been detected	<i>Aspergillus terreus</i> conserved hypothetical protein (XP_001216999.1)	62	GME2763
<i>mrr7</i>	999/332	Enoyl-(Acyl carrier protein) reductase	<i>Neosartorya fischeri</i> oxidoreductase, short-chain dehydrogenase/reductase family (XP_001259935.1)	75	GME2764
<i>mrr8</i>	1974/657	AMP-binding enzyme	<i>Neosartorya fischeri</i> long-chain fatty acid transporter, putative (XP_001257846.1)	70	GME2765

## 2. Comparison of citrinin biosynthesis gene clusters from *M. ruber*, *M. aurantiacus*, *M. purpureus* and *Penicillium expansum*




The genes enclosed by the red dotted line between *Monascus* spp. and *P. expansum* are highly homologous. The nucleotide identity of these marked genes reaches 99% among these three different *Monascus* strains, and their nucleotide identity with *P. expansum* reaches 81%. Note that the *orf4* gene in *M. aurantiacus* and *M. purpureus* was annotated as oxidoreductase according to the published papers, actually it is a homolog of *mr11*.

**Table S1** Description of homologous genes in citrinin gene cluster among *M. ruber*, *M. aurantiacus*, *M. purpureus* and *P. expansum*

Gene in <i>M. ruber</i>	Name	Putative Function	Homologous Gene in <i>P. expansum</i>	Protein Identity between spp. and <i>P. expansum</i> (%)	Homologous Gene in <i>M. aurantiacus</i>	Homologous Gene in <i>M. purpureus</i>
<i>mrl7</i>		Oxydoreductase	<i>pel7</i>	83	<i>ctnD</i>	-
<i>mrl6</i>		Dehydrogenase	<i>pel6</i>	89	<i>ctnE</i>	-
<i>mrl5</i>		Glyoxylase-like domain	<i>pel5</i>	87	<i>orf6</i>	-
<i>mrl4</i>		Dehydrogenase	<i>pel4</i>	90	<i>orf1</i>	<i>orf1</i>
<i>mrl3</i>		Zn <sub>2</sub> Cys <sub>6</sub> regulator	<i>pel3</i>	84	<i>ctnA</i>	<i>orf2</i>
<i>mrl2</i>		Fe(II)-dependent oxygenase	<i>pel2</i>	89	<i>orf3</i>	<i>orf3</i>
<i>mrl1</i>		Serine hydrolase	<i>pel1</i>	88	<i>orf4</i>	<i>orf4</i>
<i>citS</i>		Non-reducing PKS	<i>pe-pksCT</i>	85	<i>ma-pksCT</i>	<i>mp-pksCT</i>
<i>mrr1</i>		Transporter	<i>per1</i>	88	<i>orf5</i>	<i>orf5</i>
<i>mrr2</i>		Histidine phosphatase	-	-	<i>ctnF</i>	-
<i>mrr3</i>		Unknown protein	-	-	<i>orf7</i>	-
<i>mrr4</i>		WD40 protein	-	-	<i>ctnR</i>	-
<i>mrr5</i>		Carbonic anhydrase	-	-	<i>orf8</i>	-
<i>mrr6</i>		Unknown protein	-	-	<i>ctnG</i>	-
<i>mrr7</i>		Reductase	-	-	<i>ctnH</i>	-
<i>mrr8</i>		Transporter	-	-	<i>ctnI</i>	-

### 3. Investigation of *citS* intron 2

The spores of *M. ruber* M7 were inoculated into 100 mL PDB medium in 500 mL flask, 28 °C, 160 rpm, cultured for 3 days. The mycelium were collected and then washed with distilled water and used for genomic DNA and RNA preparation. Genomic DNA was isolated with GenElute Plant Genomic DNA Miniprep Kit (Sigma) and then used as template to amplify partial *citS* gene (cover intron 2) with primers pks-4-F/ pks-4-R. PCR products were purified and then sequenced. RNA were isolated with ZR Fungal/Bacterial RNA MiniPrep (Zymo Research) and then digested with Dnase I to remove the residual genomic DNA. The obtained RNA was used as template to do PCR with primers pks-4-F/ pks-4-R to demonstrate no genomic DNA contamination (no PCR band obtained), then was transcribed into cDNA with a RevertAid Premium Reverse Transcriptase Kit (Thermo Scientific). The transcribed cDNA was used as template to amplify partial *citS* gene (cover intron 2) with primers pks-4-F/ pks-4-R. PCR products were purified and then sequenced.



**Figure S3.1** A: Partial sequencing results of mRNA of *citS* from *M. ruber* M7 (start from the 6541<sup>th</sup> base of *citS*; a obvious mixture of two different sequences appears form the 6549<sup>th</sup> of the *citS* which is also the first nucleotide of intron 2); B: Partial sequencing results of genomic DNA of *citS* from *M. ruber* M7 (start from the 6541<sup>th</sup> base of *citS*)


#### 4. Domain analysis of citrinin polyketide synthase (CitS).

The diagram shows the CitS protein structure with domains SAT, KS, AT, PT, ACP, C-MeT, and R. The x-axis represents amino acid positions from 0 to 2600. The domains are represented by ovals: SAT (0-266), KS (391-806), AT (915-1226), PT (1308-1649), ACP (1670-1730), C-MeT (1927-2138), and R (2198-2523). An arrow points to the right, indicating the C-terminus.

Domain	Predicted Boundaries	Conserved Active Site Motif
SAT	A <sub>14</sub> – V <sub>266</sub>	G <sub>137</sub> X <sub>C</sub> XG <sub>141</sub> – active site cysteine
KS	D <sub>391</sub> – Q <sub>806</sub>	T <sub>553</sub> AC <sub>SSS</sub> <sub>558</sub> – active site cysteine
AT	F <sub>915</sub> – T <sub>1226</sub>	G <sub>998</sub> HS <sub>X</sub> G <sub>1002</sub> – active site serine
PT	V <sub>1308</sub> – V <sub>1649</sub>	H <sub>1326</sub> X <sub>9</sub> (P/T) <sub>1336</sub> / D <sub>1508</sub> X <sub>3</sub> (Q/H)X <sub>6</sub> N <sub>1519</sub> – active site residues
ACP	M <sub>1670</sub> – L <sub>1730</sub>	G <sub>1695</sub> XDSL <sub>1699</sub> – phosphopantetheine attachment site
C-MeT	F <sub>1927</sub> – G <sub>2138</sub>	G <sub>1992</sub> XGXG <sub>1996</sub> – S-adenosylmethionine binding
R	T <sub>2198</sub> – V <sub>2523</sub>	G <sub>2226</sub> XXGXXG <sub>2232</sub> Rossmann fold [NAD(P) binding] Y <sub>2392</sub> XXXX <sub>2396</sub> – active site residues


## 5. LCMS chromatograms

exp. 0 Organic extract of *A. oryzae* NSAR 1+ pTYGS·arg







exp. 1 Organic extract of *A. oryzae* NSAR 1+ *citS*




exp. 2 Organic extract of *A. oryzae* NSAR 1+ *citS* + *mrlI*-long




exp. 2' Organic extract of *A. oryzae* NSAR 1+ *citS* + *mrl1*




exp. 3 Organic extract of *A. oryzae* NSAR 1+ *citS* + *mrl1* + *mrl2*




exp. 4 Organic extract of *A. oryzae* NSAR 1+ *citS* + *mrl1* + *mrl2* + *mrl4*




exp. 5 Organic extract of *A. oryzae* NSAR 1+ *citS* + *mrl1* + *mrl2* + *mrl7*



exp. 6 Organic extract of *A. oryzae* NSAR 1+ *citS* + *mrl1* + *mrl2* + *mrl6*




exp. 7 Organic extract of *A. oryzae* NSAR 1+ *citS* + *mrl1* + *mrl2* + *mrl4* + *mrl7*







exp. 8 Organic extract of *A. oryzae* NSAR 1+ *citS* + *mrl1* + *mrl2* + *mrl6* + *mrl7*





exp. 9 Organic extract of *A. oryzae* NSAR 1+ *citS* + *mrl1* + *mrl2* + *mrl4* + *mrl6*





exp. 10 Organic extract of *A. oryzae* NSAR 1+ *citS* + *mrl1* + *mrl2* + *mrl4* + *mrl6* + *mrl7*




exp. 11 Organic extract of *M. ruber*  $\Delta$ citS





exp. 12 Organic extract of *M. ruber*  $\Delta$ mrl1





exp. 13 Organic extract of *M. ruber*  $\Delta$ mrl2



exp. 14 Organic extract of *M. ruber*  $\Delta$ mlr14





exp. 15 Organic extract of *M. ruber*  $\Delta$ ml6







exp. 16 Organic extract of *M. ruber*  $\Delta$ ml7




exp. 17 Organic extract of *A. oryzae* M-2-3 + pTYGS-arg-citS-Δ62bp




exp. 18 Organic extract of *A. oryzae* M-2-3 + pTYGS-arg-citS-Δ62bp-mrl1




exp.19 Organic extract of *A. oryzae* M-2-3 + pTYGS-arg-citS-Δ60bp




exp. 20 Organic extract of *A. oryzae* M-2-3 + pTYGS·arg·citS·Δ60bp·mrl1




exp. 21 Organic extract of *A. oryzae* M-2-3 + pTYGS-arg-citS-C<sub>2551</sub>A



exp. 22 Organic extract of *A. oryzae* M-2-3 + pTYGS·arg·citS·C<sub>2551A</sub>·mrl1




exp. 23 Organic extract of *A. oryzae* M-2-3 + pTYGS-arg-citS-mrl1-S122A






exp. 24 Organic extract of *A. oryzae* M-2-3 + pTYGS-arg-citS-mrl1-D<sub>207</sub>A












exp. 25 Organic extract of *A. oryzae* M-2-3 + pTYGS-arg-citS-mrl1-H<sub>235</sub>A












## 6. LC-HRMS data for compounds 1- 9

### UV spectra of compounds 1- 9



# Mass spectra of compounds 1- 9 (ES<sup>-</sup>)



Elemental Composition Report

Single Mass Analysis

Tolerance = 15.0 PPM / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Odd and Even Electron Ions

58 formula(e) evaluated with 3 results within limits (up to 50 closest results for each mass)

Elements Used:

C: 0-30 H: 0-60 O: 0-8 Na: 0-1

He

Q-ToF Premier UPLC-MS


31-Aug-2015

14:41:58

1: TOF MS ES+

5.23e+003

Yi He Comp-1 297 (3.046) AM (Cen,5, 75.00, Ar,10000.0,556.28,0.70,LS 5)



Minimum: -1.5  
 Maximum: 100.0 15.0 50.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Formula
273.0736	273.0739	-0.3	-1.1	6.5	57.3	C13 H14 O5 Na
	273.0763	-2.7	-9.9	9.5	52.2	C15 H13 O5
	273.0704	3.2	11.7	18.5	74.0	C22 H9

Elemental Composition Report

Single Mass Analysis

Tolerance = 15.0 PPM / DBE: min = -1.5, max = 51.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

273 formula(e) evaluated with 4 results within limits (all results (up to 1000) for each mass)

Elements Used:

C: 0-100 H: 0-100 N: 0-4 O: 0-10 Na: 0-1

He

Q-ToF Premier UPLC-MS


13-May-2014

12:19:33

1: TOF MS ES+

1.36e+003

YH III-3-236prep 307 (3.145) AM (Cen,5, 90.00, Ar,0.0,556.28,0.70,LS 5)



Minimum: -1.5  
 Maximum: 6.0 15.0 51.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Formula
237.1126	237.1127	-0.1	-0.4	5.5	738.3	C13 H17 O4
	237.1116	1.0	4.2	7.5	752.9	C12 H14 N4 Na
	237.1140	-1.4	-5.9	10.5	725.2	C14 H13 N4
	237.1103	2.3	9.7	2.5	768.2	C11 H18 O4 Na

# HR-MS of 3

## Elemental Composition Report

Page 1

### Single Mass Analysis

Tolerance = 20.0 PPM / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

459 formula(e) evaluated with 6 results within limits (up to 50 closest results for each mass)

Elements Used:

C: 0-40 H: 0-70 N: 0-10 O: 0-8 S: 0-1

He

Q-ToF Premier UPLC-MS


28-Jul-2015

08:56:22

YH III-66-Comp11 neg 291 (2.760) AM (Cen,5, 70.00, Ar,10000.0,554.26,0.70,LS 5); Cm (280:300)

1: TOF MS ES-

2.16e+004



Minimum: -1.5  
Maximum: 100.0 20.0 50.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Formula
237.1124	237.1127	-0.3	-1.3	5.5	704.9	C13 H17 O4
	237.1134	-1.0	-4.2	1.5	462.1	C6 H17 N6 O2 S
	237.1140	-1.6	-6.7	10.5	766.6	C14 H13 N4
	237.1100	2.4	10.1	6.5	848.8	C9 H13 N6 O2
	237.1161	-3.7	-15.6	0.5	322.0	C10 H21 O4 S
	237.1087	3.7	15.6	1.5	884.0	C8 H17 N2 O6

Elemental Composition Report

Single Mass Analysis

Tolerance = 10.0 mDa / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

61 formula(e) evaluated with 4 results within limits (up to 50 closest results for each mass)

Elements Used:

C: 0-25 H: 0-50 O: 0-10 Na: 0-1

He

Q-ToF Premier UPLC-MS


22-Jan-2015

11:16:21

1: TOF MS ES+

1.59e+003

Yi He III-24-E-252 490 (5.018) AM (Cen,2, 80.00, Ar,10000.0,556.28,0.70,LS 5)



Minimum: -1.5  
Maximum: 10.0 10.0 50.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Formula
253.1075	253.1076	-0.1	-0.4	5.5	53.3	C13 H17 O5
	253.1052	2.3	9.1	2.5	74.5	C11 H18 O5 Na
	253.1017	5.8	22.9	14.5	16.8	C20 H13
	253.0993	8.2	32.4	11.5	31.0	C18 H14 Na



Elemental Composition Report

Single Mass Analysis

Tolerance = 10.0 mDa / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Odd and Even Electron Ions

124 formula(e) evaluated with 9 results within limits (up to 50 closest results for each mass)

Elements Used:

C: 0-50 H: 0-60 N: 0-3 O: 0-8

He

Q-ToF Premier UPLC-MS


15-Jul-2015

13:44:27

1: TOF MS ES+

1.92e+003

YiHe III-48-prepC 265 (2.719) AM (Cen,5, 55.00, Ar,10000.0,556.28,0.70,LS 5)



Minimum: -1.5  
Maximum: 10.0 50.0 50.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Formula
280.1183	280.1185	-0.2	-0.7	6.5	57.7	C14 H18 N O5
	280.1158	2.5	8.9	2.0	71.3	C11 H20 O8
	280.1212	-2.9	-10.4	11.0	48.3	C17 H16 N2 O2
	280.1145	3.8	13.6	2.5	79.9	C9 H18 N3 O7
	280.1126	5.7	20.3	15.5	37.6	C21 H14 N
	280.1252	-6.9	-24.6	15.0	39.7	C22 H16
	280.1099	8.4	30.0	11.0	45.1	C18 H16 O3
	280.1271	-8.8	-31.4	2.0	81.0	C10 H20 N2 O7
	280.1086	9.7	34.6	11.5	51.8	C16 H14 N3 O2

# HR-MS of 6

## Elemental Composition Report

Page 1

### Single Mass Analysis

Tolerance = 10.0 mDa / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Odd and Even Electron Ions

118 formula(e) evaluated with 8 results within limits (up to 50 closest results for each mass)

Elements Used:

C: 0-50 H: 0-60 N: 0-3 O: 0-8

He


Q-ToF Premier UPLC-MS

15-Jul-2015

13:53:01

YiHe III-60-265b 243 (2.491) AM (Cen,5, 73.00, Ar,10000.0,556.28,0.70,LS 5)

1: TOF MS ES+  
3.08e+003



Minimum: -1.5  
Maximum: 10.0 50.0 50.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Formula
266.1031	266.1028	0.3	1.1	6.5	n/a	C13 H16 N O5
	266.1055	-2.4	-9.0	11.0	n/a	C16 H14 N2 O2
	266.1002	2.9	10.9	2.0	n/a	C10 H18 O8
	266.0988	4.3	16.2	2.5	n/a	C8 H16 N3 O7
	266.0970	6.1	22.9	15.5	n/a	C20 H12 N
	266.1096	-6.5	-24.4	15.0	n/a	C21 H14
	266.1114	-8.3	-31.2	2.0	n/a	C9 H18 N2 O7
	266.0943	8.8	33.1	11.0	n/a	C17 H14 O3

Elemental Composition Report

Single Mass Analysis

Tolerance = 20.0 PPM / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

795 formula(e) evaluated with 16 results within limits (up to 50 closest results for each mass)

Elements Used:

C: 0-60 H: 0-90 N: 0-11 O: 0-10 Na: 0-1

He Q-ToF Premier UPLC-MS


30-Jul-2015

09:35:07

1: TOF MS ES+

1.26e+003

YH III-65-Comp10 255 (2.608) AM (Cen,5, 70.00, Ar,10000.0,556.28,0.70,LS 5)



Minimum: -1.5  
Maximum: 100.0 20.0 50.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Formula
310.1290	310.1291	-0.1	-0.3	6.5	85.0	C15 H20 N O6
	310.1280	1.0	3.2	8.5	90.6	C14 H17 N5 O2 Na
	310.1277	1.3	4.2	12.5	95.7	C12 H12 N11
	310.1304	-1.4	-4.5	11.5	74.5	C16 H16 N5 O2
	310.1312	-2.2	-7.1	0.5	182.3	C3 H17 N11 O5 Na
	310.1267	2.3	7.4	3.5	102.8	C13 H21 N O6 Na
	310.1264	2.6	8.4	7.5	107.7	C11 H16 N7 O4
	310.1320	-3.0	-9.7	12.5	61.9	C19 H17 N3 Na
	310.1323	-3.3	-10.6	-1.5	177.1	C4 H20 N7 O9
	310.1253	3.7	11.9	9.5	114.6	C10 H13 N11 Na
	310.1250	4.0	12.9	2.5	122.1	C10 H20 N3 O8
	310.1336	-4.6	-14.8	3.5	160.4	C5 H16 N11 O5
	310.1339	-4.9	-15.8	-0.5	155.5	C7 H21 N5 O7 Na
	310.1240	5.0	16.1	4.5	128.3	C9 H17 N7 O4 Na
	310.1344	-5.4	-17.4	15.5	50.6	C21 H16 N3
	310.1232	5.8	18.7	15.5	40.8	C22 H16 N O

Elemental Composition Report

Single Mass Analysis

Tolerance = 10.0 mDa / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

71 formula(e) evaluated with 5 results within limits (up to 50 closest results for each mass)

Elements Used:

C: 0-50 H: 0-60 O: 0-10 Na: 0-1

He

Q-ToF Premier UPLC-MS


16-Jul-2015

08:10:42

YiHe III-32 265 (2.719) AM (Gen,5, 30.00, Ar,10000.0,556.28,0.70,LS 5)

1: TOF MS ES+

1.30e+003



Minimum: -1.5  
 Maximum: 10.0 50.0 50.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Formula
275.0895	275.0895	0.0	0.0	5.5	168.4	C13 H16 O5 Na
	275.0919	-2.4	-8.7	8.5	160.6	C15 H15 O5
	275.0861	3.4	12.4	17.5	181.7	C22 H11
	275.0837	5.8	21.1	14.5	182.9	C20 H12 Na
	275.0978	-8.3	-30.2	-0.5	175.5	C8 H19 O10

Elemental Composition Report

Single Mass Analysis

Tolerance = 10.0 mDa / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Odd and Even Electron Ions

35 formula(e) evaluated with 2 results within limits (up to 50 closest results for each mass)

Elements Used:

C: 0-30 H: 0-60 O: 0-10

He

Q-ToF Premier UPLC-MS


17-Jul-2015

09:23:53

1: TOF MS ES-

5.75e+003

YiHe III-32-266 329 (3.117) AM (Cen,5, 80.00, Ar,10000.0,554.26,0.70,LS 5)




Minimum: -1.5  
 Maximum: 10.0 50.0 50.0


Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Formula
265.1074	265.1076	-0.2	-0.8	6.5	38.4	C14 H17 O5
	265.1017	5.7	21.5	15.5	70.4	C21 H13

## 7. NMR data for compounds 1 - 9


### NMR data for compound 1

 <p>Chemical Formula: C<sub>13</sub>H<sub>14</sub>O<sub>5</sub> Exact Mass: 250.0841</p>		
Pos.	d <sub>H</sub> (CDCl <sub>3</sub> ) 400 MHz / ppm	d <sub>C</sub> (CDCl <sub>3</sub> ) 100 MHz / ppm
1	8.23, s, 1H	163.0
3	4.77, q, J = 6.7 Hz, 1H	81.9
4	2.97, q, J = 7.2 Hz, 1H	34.8
4A	-	139.2
5	-	123.3
6	-	184.1
7	-	100.6
8	-	177.5
8A	-	107.7
9	1.33, d, J = 6.7 Hz, 3H	18.6
10	1.21, d, J = 7.2 Hz, 3H	18.4
11	2.00, s, 3H	9.6
12	-	174.8

### NMR data for compound 2

 <p>Chemical Formula: C<sub>13</sub>H<sub>16</sub>O<sub>4</sub> Exact Mass: 236.1049</p>		
Pos.	d <sub>H</sub> (CDCl <sub>3</sub> ) 500 MHz / ppm	d <sub>C</sub> (CDCl <sub>3</sub> ) 125 MHz / ppm
1	9.91, brs, 1H	192.9
3	-	208.3
4	4.11, q, J = 6.9 Hz, 1H	48.8
4A	-	141.8
5	-	115.1
6	-	160.0
7	-	108.9
8	-	162.9
8A	-	112.3
8-OH	13.01, s, 1H	-
9	2.04, s, 3H	28.4
10	1.48, d, J = 6.9 Hz, 3H	17.0
11	2.16, brs, 3H	11.5
12	2.14, s, 3H	7.2

NMR data for compound **3**




Chemical Formula: C<sub>13</sub>H<sub>18</sub>O<sub>4</sub>  
Exact Mass: 238.1205

3.7 min

Pos.	d <sub>H</sub> (DMSO-d <sub>6</sub> ) 400 MHz / ppm	d <sub>C</sub> (DMSO-d <sub>6</sub> ) 100 MHz / ppm
1	4.56, 1H, d, <i>J</i> = 15.8 Hz 4.51, 1H, d, <i>J</i> = 15.8 Hz	40.1
3	-	96.2
4	2.61, 1H, q, <i>J</i> = 6.9 Hz	38.0
4A	-	135.3
5	-	113.7
6	-	152.1
7	-	109.9
8	-	148.2
8A	-	112.7
9	1.36, 3H, s	27.1
10	0.97, 3H, d, <i>J</i> = 6.9 Hz	18.8
11	1.98, 3H, s	9.9
12	2.01, 3H, s	10.9

NMR data for compound **4**




Chemical Formula: C<sub>13</sub>H<sub>16</sub>O<sub>5</sub>  
Exact Mass: 252.0998

Pos.	d <sub>H</sub> (CD <sub>3</sub> OD) 400 MHz / ppm	d <sub>C</sub> (CD <sub>3</sub> OD) 100 MHz / ppm
1	9.94, s, 1H	194.5
3	-	211.0
4	4.39, q, <i>J</i> = 6.93 Hz, 1H	50.4
4A	-	145.8
5	-	118.6
6	-	165.1
7	-	109.8
8	-	163.9
8A	-	112.8
9	2.03, s, 3H	29.2
10	1.45, d, <i>J</i> = 6.93 Hz, 3H	16.9
11	2.11, s, 3H	11.6
12	4.72, s, 2H	66.0

NMR data for compound 5


Pos.	$d_H$ (DMSO-d6) 400 MHz / ppm	$d_C$ (DMSO-d6) 100 MHz / ppm
1	8.61, s, 1H.	155.2
3	-	87.2
4	3.26, q, $J = 7.2$ , 1H.	38.8
4A	-	146.5
5	-	116.0
6	-	175.6
7	-	100.6
8	(O) 16.61, s, 1H.	175.4
8A	-	102.7
9	1.55, 3H.	18.7
10	0.96, d, $J = 7.2$ , 3H.	16.2
11	1.98, s, 3H.	9.5
12	17.02, s, 1H.	170.6
13	3.11, s, 3H.	50.1



Chemical Formula:  $C_{14}H_{17}NO_5$   
Exact Mass: 279.1107

NMR data for compound 6


Pos.	A hemiaminal diastereomer 1		B hemiaminal diastereomer 2	
	$d_H$ (DMSO-d6) 400 MHz / ppm	$d_C$ (DMSO-d6) 100 MHz / ppm	$d_H$ (DMSO-d6) 400 MHz / ppm	$d_C$ (DMSO-d6) 100 MHz / ppm
1	8.38, s, 1H.	154.2	8.54, s, 1H.	154.7
3	-	85.8	-	83.1
4	3.12, q, $J = 7.1$ , 1H.	40.4	3.19, q, $J = 7.2$ , 1H.	39.9
4A	-	146.1	-	146.6
5	-	115.4	-	115.7
6	-	173.8	-	174.5
7	-	100.3	-	100.9
8	(OH) 16.54, s, 1H.	175.4	(OH) 16.67, s, 1H.	175.5
8A	-	101.2	-	102.3
9	1.39, s, 3H.	26.0	1.57, 3H.	24.7
10	1.00, d, $J = 7.1$ , 3H.	14.0	0.92, d, $J = 7.2$ , 3H.	16.5
11	2.001, s, 3H.	9.5	1.995, s, 3H.	9.5
12	16.92, s, 1H.	169.0	16.99, s, 1H.	169.6




Chemical Formula:  $C_{13}H_{15}NO_5$   
Exact Mass: 265.0950




NMR data for compound **7**

 <p>Chemical Formula: C<sub>15</sub>H<sub>19</sub>NO<sub>6</sub> Exact Mass: 309.1212</p>		
Pos.	d <sub>H</sub> (DMSO-d <sub>6</sub> ) 400 MHz / ppm	d <sub>C</sub> (DMSO-d <sub>6</sub> ) 100 MHz / ppm
1	8.45, 1H, s	143.5
3	-	90.6
4	3.18, 1H, m	41.7
4A	-	145.9
5	-	115.5
6	-	174.0
7	-	110.1
8	(OH) 14.55, 1H, s	158.7
8A	-	101.1
9	1.35, 3H, s	24.2
10	1.02, 1H, d, <i>J</i> = 7.0 Hz	14.0
11	2.01, 3H, s	10.7
12	(OH) 16.90, 1H, s	173.4
13	3.75, 1H, m, 3.91, 1H, m	53.2
14	3.77, 1H, m, 3.64, 1H, m	59.4

NMR data for compound **8**


 <p>Chemical Formula: C<sub>13</sub>H<sub>16</sub>O<sub>5</sub> Exact Mass: 252.0998</p>		
Pos.	d <sub>H</sub> (DMSO-d <sub>6</sub> ) 400 MHz / ppm	d <sub>C</sub> (DMSO-d <sub>6</sub> ) 100 MHz / ppm
1	4.59, d, <i>J</i> = 9.4 Hz, 1H 4.53, d, <i>J</i> = 9.4 Hz, 1H	58.5
3	-	96.1
4	2.71, q, <i>J</i> = 6.95 Hz, 1H	39.1
4A	-	150.1
5	-	114.0
6	-	157.7
7	-	109.5
8	-	155.0
8A	-	112.4
9	1.38, s, 3H	26.8
10	1.01, d, <i>J</i> = 6.95 Hz, 3H	18.6
11	1.98, s, 3H	9.8
12	10.22, s, 1H	194.6

## 7.1 NMR Spectra Compound 1




Compound 1  $^1\text{H}$  NMR  $\text{CDCl}_3$ , 400 MHz.






Compound 1 HSQC




Compound 1 <sup>13</sup>C NMR CDCl<sub>3</sub> 100 MHz




**Compound 1 HMBC**

## 7.2 NMR Spectra Compound 2




Compound 2  $^1\text{H}$  NMR  $\text{CDCl}_3$  500 MHz




**Compound 2 COSY**






Compound 2  $^{13}\text{C}$  NMR  $\text{CDCl}_3$  125 MHz





Compound 2 HSQC




**Compound 2 HMBC**

### 7.3 NMR Spectra Compound 3







**Compound 3  $^1\text{H}$  NMR  $\text{DMSO-d}_6$  100 MHz**



**Compound 3 COSY**




**Compound 3 HMBC Expansion**




**Compound 3 HMBC Expansion**





**Compound 3 HMBC Expansion**


## 7.4 NMR Spectra Compound 4




Compound 4  $^1\text{H}$  NMR  $\text{CD}_3\text{OD}$  400 MHz




**Compound 4 COSY**



Compound 4  $^{13}\text{C}$  NMR  $\text{CD}_3\text{OD}$  100 MHz




**Compound 4 HSQC**



Compound 4 HMBC

## 7.5 NMR Spectra Compounds 5 + 6 (mix of diastereomers)




Compound 5+6 <sup>1</sup>H NMR, DMSO-d6 400 MHz



**Compound 5+6**






**Mixture of 5 and diastereomers of 6.**


Methyl-10 of 5, d at 0.96 ppm; Methyl-10 of 6-major d at 0.92 ppm; Methyl-10 of 6-minor d at 1.00 ppm.

Triplet at 1.06 ppm from contamination.




**Compound 5+6 <sup>13</sup>C NMR DMSO-d6 100 MHz**

pdata/1  
Yi He YH 483 6,3mg in DMSO-d6 at 298.0K, 03.07.2015 Koertje  
13C-NMR, BB  
YH-III-48 prep c




Compound 5+6 <sup>13</sup>C Expansion

pdata/1  
YI He YH 483 6.3mg in DMSO-d6 at 298.0K, 03.07.2015 Koertje  
13C-NMR, BB  
YH-III-48 prep c




Compound 5+6 <sup>13</sup>C Expansion




**Compound 5+6  $^{13}\text{C}$  Expansion**


pdata/1  
Yi He YH 483 6.3mg in DMSO-d6 at 298.0K, 03.07.2015 Koertje  
13C-NMR, BB  
YH-III-48 prep c



Compound 5+6 <sup>13</sup>C Expansion




**Compound 5+6 HSQC**




**Compound 5+6 HSQC Expansion**







**Compound 5+6 HMBC**



**Compound 5+6 HMBC Expansion**




**Compound 5+6 HMBC Expansion**




Compound 5+6 HMBC Expansion

## 7.7 NMR Spectra Compound 7 (mixture of diastereomers) + 6 and other degradation products.

7 was isolated by rapid mass-directed reverse-phase purification. Solvent was evaporated, NMR solvent (DMSO-d<sub>6</sub>) was added and NMR spectra gained as quickly as possible. However spectra always contain traces of 6 and other degradation products. 7 was identified as the only component of the mixture consistent with the measured HRMS data indicating a molecular formula of C<sub>15</sub>H<sub>19</sub>NO<sub>6</sub>. In particular HMBC correlations confirmed the skeleton as the same as 6, and also the location of the CH<sub>2</sub>CH<sub>2</sub>OH group (HMBC from H-1 to C-13).




HMBC H → C Correlations




Compound 7 <sup>1</sup>H NMR DMSO-d<sub>6</sub> 400 MHz


YHHA651O/10  
Yi He YH 651 4mg in DMSO-d6 at 298.0K, 24.07.2015, Koertje  
1H-1d  
YH-II-65 Comp 10, prep MW 309



**Compound 7 <sup>1</sup>H NMR**




**Compound 7 HMBC Expansion**




**Compound 7 HMBC Expansion** - sample too weak to show HMBC correlations from the heavily coupled 13- and 14-protons






**Compound 7 HMBC Expansion** - showing presence of a second minor diastereomer and **6**.




**Compound 7 HMBC Expansion**

HMBC #7




Compound 7 HMBC Expansion




Compound 7 HMBC Expansion - key correlations from H-1


HSQC #7.



Compound 7 HSQC Expansion




**Compound 7 HSQC Expansion**



**Compound 7 HSQC Expansion**


HSQC #7




**Compound 7 HSQC Expansion**



## 7.8 NMR Spectra Compound 8




Compound 8  $^1\text{H}$  NMR DMSO- $d_6$  400 MHz




### Compound 8 COSY


YHCL678O/1  
Y1 He YH 678 5.2mg in DMSO-d6 at 298.0K, 12.08.2015 Rettstadt  
YH 678 Comp8  
13C-BB




**Compound 8  $^{13}\text{C}$  NMR DMSO-d6 100 MHz**



**Compound 8 HMBC Expansion.** Note that aldehyde C-H coupling of *ca* 8 Hz means that aldehyde shows in HMBC spectrum and not in HSQC.



**Compound 8 HMBC Expansion**




Compound 8 HMBC Expansion



**Compound 8 HSQC**

## 7.9 NMR Spectra Compound 9


Insufficient **9** was purified to collect full 2D data - in particular correlations from H-12 to C-12, C-6, C-7 and C-8 are too weak to observe. However comparison of the extant NMR data with that of **8** and HRMS data suggest it is the methyl acetal **9**.




Compound **9**  $^1\text{H}$  NMR  $\text{CD}_3\text{OD}$  400 MHz




YHCL323O/10  
Yi He YH 323 3,5mg in CD3OD at 298.0K, 03.02.2015 Koertje  
13C-NMR,BB




**Compound 9 CDCl<sub>3</sub> <sup>13</sup>C NMR 100 MHz**



**Compound 9 COSY**



Compound 9 HMBC expansion



Compound 9 HSQC

## 8. Experimental Section

### 8.1 General

LC-MS data were obtained with using a Waters LCMS system comprising of a Waters 2767 autosampler, Waters 2545 pump system, a Phenomenex Kinetex column (2.6  $\mu$ , C<sub>18</sub>, 100 Å, 4.6 × 100 mm) equipped with a Phenomenex Security Guard precolumn (Luna C<sub>5</sub> 300 Å) eluted at 1 mL/min. Detection was by Waters 2998 Diode Array detector between 200 and 600 nm; Waters 2424 ELSD and Waters SQD-2 mass detector operating simultaneously in ES+ and ES- modes between 100 *m/z* and 650 *m/z*. Solvents were: A, HPLC grade H<sub>2</sub>O containing 0.05% formic acid; B, HPLC grade MeOH containing 0.045% formic acid; and C, HPLC grade CH<sub>3</sub>CN containing 0.045% formic acid. Gradients were as follows. *Method 1*. Kinetex/CH<sub>3</sub>CN: 0 min, 10% C; 10 min, 90% C; 12 min, 90% C; 13 min, 10% C; 15 min, 10% C.

### Semi-Preparative LCMS and compound purification.

Purification of compounds was generally achieved using a Waters mass-directed autopurification system comprising of a Waters 2767 autosampler, Waters 2545 pump system, a Phenomenex Kinetex Axia column (5 $\mu$ , C<sub>18</sub>, 100 Å, 21.2 × 250 mm) equipped with a Phenomenex Security Guard precolumn (Luna C<sub>5</sub> 300 Å) eluted at 20 mL/min at ambient temperature. Solvent A, HPLC grade H<sub>2</sub>O + 0.05% formic acid; Solvent B, HPLC grade CH<sub>3</sub>CN + 0.045% formic acid. The post-column flow was split (100:1) and the minority flow was made up with HPLC grade MeOH + 0.045% formic acid to 1 mL·min<sup>-1</sup> for simultaneous analysis by diode array (Waters 2998), evaporative light scattering (Waters 2424) and ESI mass spectrometry in positive and negative modes (Waters SQD-2). Detected peaks were collected into glass test tubes. Combined tubes were evaporated under a flow of dry N<sub>2</sub> gas, weighed, and residues dissolved directly in NMR solvent for NMR analysis.

### 8.2 General techniques for DNA manipulation

Polymerase chain reactions were performed with PrimeSTAR<sup>®</sup> HS DNA Polymerase (TaKaRa Bio Inc.). Restriction digests were carried out according to the manufacturer's protocols (NEB, Fermentas, Promega). The primers used to amplify each fragment were synthesized by Sigma, and are listed in Table S2.


### 8.3 Strains and culturing

*Escherichia coli* TOP10 (Invitrogen) was used as the host for plasmids that did not contain a Gateway destination cassette. Gateway destination vectors were propagated in *E.coli* *ccdB* Survival<sup>™</sup> 2 T1R cells (Invitrogen). *Saccharomyces cerevisiae* strain YPH499 (Stratagene) was used as the host for plasmid assembly by homologous recombination. *Aspergillus oryzae* strain NSAR1, a quadruple auxotrophic (*niaD*<sup>-</sup> *sC*<sup>-</sup> *ΔargB* *adeA*<sup>-</sup>) host, was used for heterologous expression of citrinin gene cluster, and routinely maintained at 28 °C on DPY (2% (w/v) dextrin from potato starch, 1% (w/v) polypeptone, 0.5% (w/v) yeast extract, 0.5% (w/v) monopotassium phosphate, 0.05% (w/v) magnesium sulfate, 2.5% (w/v) agar) plate. *A. oryzae*

strainM-2-3, an arginine auxotroph, was obtained from Professor Teruo Fujii, the University of Tokyo and mycelium was routinely maintained at 28 °C on MEA (3.36% malt extract agar) plate.

#### 8.4 Cloning procedures for heterologous expression of citrinin genes in *A. oryzae* NSAR1

**8.4.1 exp. 1:** The *citS* gene was amplified from *M. ruber* M7 genomic DNA as four fragments using primers pks-1-F/pks-1-R, pks-2-F/pks-2-R, pks-3-F/pks-3-R, pks-4-F/pks-4-R according to the strategy described in Fig. S8.1. These fragments with overlaps with each other were reassembled by homologous recombination in *S. cerevisiae* with *NotI* and *AscI* cut pE-YA vector and shuttled back into *E. coli* to create pE-YA·*citS* (the only 56-bp intron in *citS* based on bioinformatics analysis was removed). The cloned *citS* gene with the only 56-bp intron removed was then transferred into pTYGS·arg by Gateway LR recombination (Invitrogen) to create pTYGS·arg·*citS*. Thus, the *citS* gene was placed under the control of  $P_{amyB}$  and  $T_{amyB}$ . Transformation of *A. oryzae* NSAR1 with this plasmid yielded 8 transformants.



**Figure S8.1** Cloning strategy of *citS* to yield pE-YA·*citS*

**8.4.2 exp. 2:** The long 942-bp *mrl1* gene was amplified from *M. ruber* M7 cDNA as a single fragment using primers mrl1-F-long and mrl1-R which flanked the PCR product with sequences overlapping the 3' terminal of alcohol dehydrogenase promoters ( $P_{adh}$ ) and the 5' terminal of enolase terminator ( $T_{eno}$ ). This fragment was cloned into *AscI-cut* pTYGS·arg·*citS* under the control of  $P_{adh}$  and  $T_{eno}$  by homologous recombination in *S. cerevisiae* and shuttled back into *E. coli* to create pTYGS·arg·*citS*·*mrl1*-long. Transformation of *A. oryzae* NSAR1 with this plasmid yielded 13 transformants.

**exp. 2':** The short *mrl1* gene with first 156 bp nucleotides removed (define as *mrl1* gene in this MS) was amplified from *M. ruber* M7 cDNA as a single fragment using primers mrl1-F and mrl1-R which flanked the PCR product with sequences overlapping the 3' terminal of  $P_{adh}$  and the 5' terminal of  $T_{eno}$ . The same method was used to create pTYGS·arg·*citS*·*mrl1*. Transformation of *A. oryzae* NSAR1 with this plasmid yielded 10 transformants.

**8.4.3 exp. 3:** The *mrl2* gene was amplified from *M. ruber* M7 cDNA as a single fragment using primers mrl2-F and mrl2-R-b which flanked the PCR product with sequences overlapping  $P_{adh}$  and  $T_{eno}$ . This fragment was cloned into *AscI-cut* pTYGS·ade under the control of  $P_{adh}$  and  $T_{eno}$  by homologous recombination in *S. cerevisiae* and shuttled back into *E. coli* to create pTYGS·ade·*mrl2*. Transformation of *A. oryzae* NSAR1 harboring pTYGS·arg·*citS*·*mrl1* with this plasmid yielded 10 transformants.

**8.4.4 exp. 4:** The *mrl2* and *mrl4* genes were amplified from *M. ruber* M7 cDNA as single fragment using primers mrl2-F/mrl2-R and mrl4-F/mrl4-R-b respectively. The cloned *mrl2* gene was 5' flanked by a 30-bp nucleotides overlap with  $P_{adh}$  and 3' flanked by a 30-bp nucleotides overlap with the alcohol dehydrogenase terminator ( $T_{adh}$ ). The cloned *mrl4* gene was 5' flanked by a 30-bp nucleotides overlap with the glyceraldehyde-3-phosphate dehydrogenase promoter ( $P_{gpdA}$ ) and 3' flanked by a 30-bp nucleotides overlap with  $T_{eno}$ . These two fragments together with a patch fragment  $T_{adh}$ - $P_{gpdA}$  (gel purified from *AscI* digested pTYGS·ade vector) were cloned into *AscI-cut* pTYGS·ade by homologous recombination in *S. cerevisiae* and shuttled back into *E. coli* to create pTYGS·ade·*mrl2*·*mrl4*. Transformation of *A. oryzae* NSAR1 harboring pTYGS·arg·*citS*·*mrl1* with this plasmid yielded 22 transformants.

**8.4.5 exp. 5:** The *mrl7* gene was amplified from *M. ruber* M7 cDNA as a single fragment using primers mrl7-F and mrl7-R which flanked the PCR product with sequences overlapping the upstream and downstream of *NotI* and *AscI* cut pE-YA vector. This fragment was reassembled by homologous recombination in *S. cerevisiae* with *NotI* and *AscI* cut pE-YA vector and shuttled back into *E. coli* to create pE-YA·*mrl7*. The cloned *mrl7* gene was then transferred into pTYGS·ade·*mrl2* by Gateway LR recombination to create pTYGS·ade·*mrl2*·*mrl7*. Thus, the *mrl7* gene was placed under the control of  $P_{amyB}$  and  $T_{amyB}$ . Transformation of *A. oryzae* NSAR1 harboring pTYGS·arg·*citS*·*mrl1* with this plasmid yielded 16 transformants.

**8.4.6 exp. 6:** The *mrl2* and *mrl6* genes were amplified from *M. ruber* M7 cDNA as single fragment using primers *mrl2*-F/*mrl2*-R and *mrl6*-F-b/*mrl6*-R respectively. The cloned *mrl2* gene was 5' flanked by a 30-bp nucleotides overlap with *P<sub>adh</sub>* and 3' flanked by a 30-bp nucleotides overlap with the *T<sub>adh</sub>*. The cloned *mrl6* gene was 5' flanked by a 30-bp nucleotides overlap with the *P<sub>gpdA</sub>* and 3' flanked by a 30-bp nucleotides overlap with *T<sub>eno</sub>*. These two fragments together with a patch fragment *T<sub>adh</sub>-P<sub>gpdA</sub>* (gel purified from *AscI* digested pTYGS·ade vector) were cloned into *AscI*-cut pTYGS·ade by homologous recombination in *S. cerevisiae* and shuttled back into *E. coli* to create pTYGS·ade·*mrl2*·*mrl6*. Transformation of *A. oryzae* NSAR1 harboring pTYGS·arg·*citS*·*mrl1* with this plasmid yielded 27 transformants.

**8.4.7 exp. 7:** The constructed vector pE-YA·*mrl7* in 8.4.5 was used to do Gateway LR recombination with pTYGS·ade·*mrl2*·*mrl4* which constructed in 8.4.4 to create pTYGS·ade·*mrl2*·*mrl4*·*mrl7*. Transformation of *A. oryzae* NSAR1 harboring pTYGS·arg·*citS*·*mrl1* with this plasmid yielded 24 transformants.

**8.4.8 exp. 8:** The constructed vector pE-YA·*mrl7* in 8.4.5 was used to do Gateway LR recombination with pTYGS·ade·*mrl2*·*mrl6* which constructed in 8.4.6 to create pTYGS·ade·*mrl2*·*mrl6*·*mrl7*. Transformation of *A. oryzae* NSAR1 harboring pTYGS·arg·*citS*·*mrl1* with this plasmid yielded 41 transformants.


**8.4.9 exp. 9:** The *mrl2*, *mrl4* and *mrl6* genes were amplified from *M. ruber* M7 cDNA as single fragment using primers *mrl2*-F/*mrl2*-R, *mrl4*-F/*mrl4*-R and *mrl6*-F/*mrl6*-R respectively. The cloned *mrl2* gene was 5' flanked by a 30-bp nucleotides overlap with *P<sub>adh</sub>* and 3' flanked by a 30-bp nucleotides overlap with *T<sub>adh</sub>*. The cloned *mrl4* gene was 5' flanked by a 30-bp nucleotides overlap with *P<sub>gpdA</sub>* and 3' flanked by a 30-bp nucleotides overlap with the glyceraldehyde-3-phosphate dehydrogenase terminator (*T<sub>gpdA</sub>*). The cloned *mrl6* gene was 5' flanked by a 30-bp nucleotides overlap with the enolase promoter (*P<sub>eno</sub>*) and 3' flanked by a 30-bp nucleotides overlap with *T<sub>eno</sub>*. Digestion of pTYGS·ade with *AscI* generates three fragments: the pTYGS·ade vector plus *P<sub>adh</sub>* in one terminal and *T<sub>eno</sub>* in the other terminal (11749 bp), *T<sub>adh</sub>-P<sub>gpdA</sub>* (2488 bp), and *T<sub>gpdA</sub>-P<sub>eno</sub>* (808 bp). These three gel purified fragments together with the cloned *mrl2*, *mrl4* and *mrl6* genes were reassembled by homologous recombination in *S. cerevisiae* and shuttled back into *E. coli* to create pTYGS·ade·*mrl2*·*mrl4*·*mrl6*. Transformation of *A. oryzae* NSAR1 harboring pTYGS·arg·*citS*·*mrl1* with this plasmid yielded 33 transformants.

**8.4.10 exp. 10:** The constructed vector pE-YA·*mrl7* in 8.4.5 was used to do Gateway LR recombination with pTYGS·ade·*mrl2*·*mrl4*·*mrl6* which constructed in 8.4.9 to create pTYGS·ade·*mrl2*·*mrl4*·*mrl6*·*mrl7*. Transformation of *A. oryzae* NSAR1 harboring pTYGS·arg·*citS*·*mrl1* with this plasmid yielded 15 transformants.



## 8.5 Gene knock-out procedures, schemes in *M. ruber* M7


**8.5.1 exp. 11: gene knock-out of *citS*.** The *citS* gene knock-out strategy was designed to insert the 1.2 kb neomycin phosphotransferase resistance gene (*neo*) which was amplified by PCR from pKN1 using the primers G418F and G418R into the internal of *citS*. A 721 bp of 5' fragment and a 954 bp of 3' fragment of *citS* were amplified from *M. ruber* M7 genomic DNA using primers pksCT-5F/pksCT-5R and pksCT-3F/pksCT-3R respectively and served as homologous arms for recombination event (Fig. S8.2A). These three fragments were reassembled by homologous recombination in *S. cerevisiae* with *NotI* and *AscI* cut pE-YA vector and shuttled back into *E. coli* to create pE-YA-*citS*-KO. Then both pE-YA-*citS*-KO and pCAMBIA3300 were digested with *SalI* and *HindIII* and ligated by T4 DNA ligase to create pC3300-*citS*. This plasmid was transformed into *Agrobacterium tumefaciens* EHA105 afterwards. Subsequently, *A. tumefaciens* mediated transformation (ATMT) was performed with Mr $\Delta$ ku80 strain (a *ku80* knock-out mutant of *M. ruber* M7). A *citS* knock-out mutant ( $\Delta$ *citS*::*neo*) was confirmed by analytical PCR (Fig. S8.2B). A 1410 bp fragment was expected to amplify from the WT (Mr $\Delta$ ku80) genomic DNA using primers pksCT-VF and pksCT-VR, while nothing was obtained from the *citS* knock-out mutant. A 1.2 kb fragment of the *neo* gene could be amplified using primers G418F and G418R from the *citS* knock-out mutant, while no PCR product got from the WT sample.



**Figure S8.2** Scheme to knock-out *citS* (A) and PCR verification of  $\Delta$ *citS*::*neo* mutant (B)

Lanes 1/3 and 2/4 were PCR results to amplify partial *citS* gene and *neo* with primers pksCT-VF/pksCT-VR and G418F/G418R respectively. Lane 1 and 2 were using gDNA of  $\Delta$ *citS*::*neo* mutant as template, lane 3 and 4 were using gDNA of Mr $\Delta$ ku80 strain as template. M: NEB 1 kb DNA ladder.

**8.5.2 exp. 12: gene knock-out of *mrll*.** The similar strategy was used to inactivate *mrll*. A 611 bp of 5' fragment and a 594 bp of 3' fragment of *mrll* were amplified from *M. ruber* M7 genomic DNA using primers *mrll*-5F/*mrll*-5R and *mrll*-3F/*mrll*-3R respectively and served as homologous arms for recombination event (Fig. S8.3A). These two fragments together with the *neo* gene were reassembled as a knock-out cassette by homologous recombination in *S. cerevisiae* with *NotI* and *AscI* cut pE-YA vector and shuttled back into *E. coli* to create pE-YA-*mrll*-KO. *KpnI* and *XbaI* digestion and T4 DNA ligation of pE-YA-*mrll*-KO and pCAMBIA3300 yielded pC3300-*mrll*. The same ATMT method was used to obtain *mrll* knock-out mutant ( $\Delta$ *mrll*::*neo*). Analytical PCR verified the homologous recombination at the right position in the *mrll* knock-out mutant (Fig. S8.3B). A 633 bp fragment was expected to amplify from the WT (Mr $\Delta$ ku80) genomic DNA using primers *mrll*-VF and *mrll*-VR, while nothing was obtained from the *mrll* knock-out mutant. A 1.2 kb fragment of the *neo* gene could be amplified using primers G418F and G418R from the *mrll* knock-out mutant, while no PCR product got from the WT sample.




**Figure S8.3** Scheme to knock-out *mrll* (A) and PCR verification of  $\Delta$ *mrll*::*neo* mutant (B)

Lanes 1/3 and 2/4 were PCR results to amplify partial *mrll* gene and *neo* with primers *mrll*-VF/*mrll*-VR and G418F/G418R respectively. Lane 1 and 2 were using gDNA of  $\Delta$ *mrll*::*neo* mutant as template, lane 3 and 4 were using gDNA of Mr $\Delta$ ku80 strain as template. M: NEB 1 kb DNA ladder.

**8.5.3 exp. 13: gene knock-out of *mrll*.** The similar strategy was used to inactivate *mrll*. A 520 bp of 5' fragment and a 489 bp of 3' fragment of *mrll* were amplified from *M. ruber* M7 genomic DNA using primers *mrll*-5F/*mrll*-5R and *mrll*-3F/*mrll*-3R respectively and served as homologous arms for recombination event (Fig. S8.4A). These two fragments together with the *neo* gene were reassembled as a knock-out cassette by homologous

recombination in *S. cerevisiae* with *NotI* and *AscI* cut pE-YA vector and shuttled back into *E. coli* to create pE-YA-*mrl2*-KO. *KpnI* and *XbaI* digestion and T4 DNA ligation of pE-YA-*mrl2*-KO and pCAMBIA3300 yielded pC3300-*mrl2*. The same ATMT method was used to obtain *mrl2* knock-out mutant ( $\Delta mrl2::neo$ ). Analytical PCR verified the homologous recombination at the right position in the *mrl2* knock-out mutant (Fig. S8.4B). Briefly, part of *mrl2* (537 bp) could only be amplified from the WT and *neo* could only be amplified from the *mrl2* knock-out mutant using primers *mrl2*-VF/*mrl2*-VR and G418F/G418R respectively, while the other two situations yielded no PCR products.




**Figure S8.4** Scheme to knock-out *mrl2* (A) and PCR verification of  $\Delta mrl2::neo$  mutant (B)

Lanes 1/3 and 2/4 were PCR results to amplify partial *mrl2* gene and *neo* with primers *mrl2*-VF/*mrl2*-VR and G418F/G418R respectively. Lane 1 and 2 were using gDNA of  $\Delta mrl2::neo$  mutant as template, lane 3 and 4 were using gDNA of MrΔku80 strain as template. M: NEB 1 kb DNA ladder.

**8.5.4 exp. 14: gene knock-out of *mrl4*.** The similar strategy was used to inactivate *mrl4*. A 839 bp of 5' fragment and a 520 bp of 3' fragment of *mrl4* were amplified from *M. ruber* M7 genomic DNA using primers *mrl4*-5F/*mrl4*-5R and *mrl4*-3F/*mrl4*-3R respectively and served as homologous arms for recombination event (Fig. S8.5A). These two fragments together with the *neo* gene were reassembled as a knock-out cassette by homologous recombination in *S. cerevisiae* with *NotI* and *AscI* cut pE-YA vector and shuttled back into *E. coli* to create pE-YA-*mrl4*-KO. *XbaI* and *HindIII* digestion and T4 DNA ligation of pE-YA-*mrl4*-KO and pCAMBIA3300 yielded pC3300-*mrl4*. The same ATMT method was used to obtain *mrl4* knock-out mutant ( $\Delta mrl4::neo$ ). Analytical PCR verified the homologous recombination at the right position in the *mrl4* knock-out mutant (Fig. S8.5B). Briefly, part of *mrl4* (740 bp) could only be amplified from the WT and *neo* could only be amplified from the *mrl4* knock-out mutant using primers


*mrl4*-VF/*mrl4*-VR and G418F/G418R respectively, while the other two situations yielded no PCR products.



**Figure S8.5** Scheme to knock-out *mrl4* (A) and PCR verification of  $\Delta mrl4::neo$  mutant (B)

Lanes 1/3 and 2/4 were PCR results to amplify partial *mrl4* gene and *neo* with primers *mrl4*-VF/*mrl4*-VR and G418F/G418R respectively. Lane 1 and 2 were using gDNA of  $\Delta mrl4::neo$  mutant as template, lane 3 and 4 were using gDNA of MrΔku80 strain as template. M: NEB 1 kb DNA ladder.


**8.5.5 exp. 15: gene knock-out of *mrl6*.** The similar strategy was used to inactivate *mrl6*. A 542 bp of 5' fragment and a 576 bp of 3' fragment of *mrl6* were amplified from *M. ruber* M7 genomic DNA using primers *mrl6*-5F/*mrl6*-5R and *mrl6*-3F/*mrl6*-3R respectively and served as homologous arms for recombination event (Fig. S8.6A). These two fragments together with the *neo* gene were reassembled as a knock-out cassette by homologous recombination in *S. cerevisiae* with *NotI* and *AscI* cut pE-YA vector and shuttled back into *E. coli* to create pE-YA-*mrl6*-KO. *KpnI* and *XbaI* digestion and T4 DNA ligation of pE-YA-*mrl6*-KO and pCAMBIA3300 yielded pC3300-*mrl6*. The same ATMT method was used to obtain *mrl6* knock-out mutant ( $\Delta mrl6::neo$ ). One mutant was confirmed by analytical PCR (Fig. S8.6B). Part of *mrl6* (829 bp) could only be amplified from the WT and *neo* could only be amplified from the *mrl6* knock-out mutant using primers *mrl6*-VF/*mrl6*-VR and G418F/G418R respectively, while the other two situations yielded no PCR products.



**Figure S8.6** Scheme to knock-out *mrl6* (A) and PCR verification of  $\Delta mrl6::neo$  mutant (B)

Lanes 1/3 and 2/4 were PCR results to amplify partial *mrl6* gene and *neo* with primers *mrl6*-VF/*mrl6*-VR and G418F/G418R respectively. Lane 1 and 2 were using gDNA of  $\Delta mrl6::neo$  mutant as template, lane 3 and 4 were using gDNA of MrΔku80 strain as template. M: NEB 1 kb DNA ladder.

**8.5.6 exp. 16: gene knock-out of *mrl7*.** The similar strategy was used to inactivate *mrl7*. A 878 bp of 5' fragment and a 536 bp of 3' fragment of *mrl7* were amplified from *M. ruber* M7 genomic DNA using primers *mrl7*-5F/*mrl7*-5R and *mrl7*-3F/*mrl7*-3R respectively and served as homologous arms for recombination event (Fig. S8.7A). These two fragments together with the *neo* gene were reassembled as a knock-out cassette by homologous recombination in *S. cerevisiae* with *NotI* and *AscI* cut pE-YA vector and shuttled back into *E. coli* to create pE-YA-*mrl7*-KO. *KpnI* and *XbaI* digestion and T4 DNA ligation of pE-YA-*mrl7*-KO and pCAMBIA3300 yielded pC3300-*mrl7*. The same ATMT method was used to obtain *mrl7* knock-out mutant ( $\Delta mrl7::neo$ ). One mutant was confirmed by analytical PCR (Fig. S8.7B). Part of *mrl7* (491 bp) could only be amplified from the WT and *neo* could only be amplified from the *mrl7* knock-out mutant using primers *mrl7*-VF/*mrl7*-VR and G418F/G418R respectively, while the other two situations yielded no PCR products.



**Figure S8.7** Scheme to knock-out *mrl7* (A) and PCR verification of  $\Delta mrl7::neo$  mutant (B)

Lanes 1/3 and 2/4 were PCR results to amplify partial *mrl7* gene and *neo* with primers *mrl7*-VF/*mrl7*-VR and G418F/G418R respectively. Lane 1 and 2 were using gDNA of  $\Delta mrl7::neo$  mutant as template, lane 3 and 4 were using gDNA of MrΔku80 strain as template. M: NEB 1 kb DNA ladder.


## 8.6 Cloning procedures for heterologous expression of different intron removed *citS* gene

**8.6.1 exp. 17: construction of pTYGS·arg·*citS*·Δ62bp** (*citS* removed both 56 bp intron 1 and 62 bp intron 2). The primers and the cloning procedures were the same with 8.4.1, the only difference was *M. ruber* M7 cDNA was used as PCR template. The constructed pTYGS·arg·*citS*·Δ62bp was sequenced to make sure both the 56 bp intron 1 and 62 bp intron 2 were correctly removed. Transformation of *A. oryzae* M-2-3 with this plasmid yielded 20 transformants.

**8.6.2 exp. 18: construction of pTYGS·arg·*citS*·Δ62bp·*mrl1*** (*citS* removed both 56 bp intron 1 and 62 bp intron 2, *mrl1*). The cloned *mrl1* gene was inserted into *AscI*-cut pTYGS·arg·*citS*·Δ62bp under the control of *P<sub>adh</sub>* and *T<sub>eno</sub>* according to the same procedure in 8.4.2 to yield pTYGS·arg·*citS*·Δ62bp·*mrl1*. Transformation of *A. oryzae* M-2-3 with this plasmid yielded 12 transformants.

**8.6.3 exp. 19: construction of pTYGS·arg·*citS*·Δ60bp** (*citS* removed 56 bp intron 1 and 60 bp intron 2). The *citS* gene removed 56 bp intron 1 and

60 bp intron 2 was amplified from *M. ruber* M7 genomic DNA as four fragments using primers pks-1-F/pks-1-R, pks-2-F/pks-2-R, pks-3-F/pks-3-R-7189, pks-4-F-7250/pks-4-R and cloned into pTYGS·arg vector according to the same strategy described in 8.4.1 to yield pTYGS·arg·*citS*·Δ60bp. Transformation of *A. oryzae* M-2-3 with this plasmid yielded 17 transformants.



**Figure S8.8** Cloning strategy to remove 60 bp intron 2

**8.6.4 exp. 20: construction of pTYGS·arg·*citS*·Δ60bp·*mrl1*** (*citS* removed 56 bp intron 1 and 60 bp intron 2, *mrl1*). The cloned *mrl1* gene was inserted into *AscI*-cut pTYGS·arg·*citS*·Δ60bp under the control of *P<sub>adh</sub>* and *T<sub>eno</sub>* according to the same procedure in 8.4.2 to yield pTYGS·arg·*citS*·Δ60bp·*mrl1*. Transformation of *A. oryzae* M-2-3 with this plasmid yielded 24 transformants.

### 8.7 Cloning procedures to mutate cysteine to alanine at position 2551 in *CitS* protein

**8.7.1 exp. 21: construction of pTYGS·arg·*citS*·C<sub>2551</sub>A** (*citS* with mutation of C<sub>2551</sub> to A). A 349-bp DNA fragment containing mutation of TGT to GCC (C<sub>2551</sub> to A) was synthesized. Then the *XbaI* cut pE-YA·*citS* was used to do yeast recombination in *S. cerevisiae* with the synthetic DNA fragment and shuttled back into *E. coli* to create pE-YA·*citS*·C<sub>2551</sub>A. Gateway LR recombination between pE-YA·*citS*·C<sub>2551</sub>A and pTYGS·arg transferred the mutant *citS* into pTYGS·arg to create pTYGS·arg·*citS*·C<sub>2551</sub>A. Transformation of *A. oryzae* M-2-3 with this plasmid yielded 20 transformants.

**8.7.2 exp. 22: construction of pTYGS·arg·*citS*·C<sub>2551</sub>A·*mrl1*** (*citS* with mutation of C<sub>2551</sub> to A, *mrl1*). The cloned *mrl1* gene was inserted into *AscI*-cut pTYGS·arg·*citS*·C<sub>2551</sub>A under the control of *P<sub>adh</sub>* and *T<sub>eno</sub>* according to the same procedure in 8.4.2 to yield pTYGS·arg·*citS*·C<sub>2551</sub>A·*mrl1*. Transformation of *A. oryzae* M-2-3 with this plasmid yielded 25 transformants.

### 8.8 Cloning procedures to mutate catalytic triad in *mrl1* protein

**8.8.1 exp. 23: construction of pTYGS·arg·*citS*·*mrl1*·S<sub>122</sub>A** (*citS*, *mrl1* with mutation of S<sub>122</sub> to A). The *mrl1* gene was amplified from *M. ruber*

cDNA as two fragments using primers *mrl1*-F/*mrl1*-R-519 and *mrl1*-F-490/*mrl1*-R. The cloned two fragments were used to do yeast recombination in *S. cerevisiae* with *AscI*-cut pTYGS·arg·*citS* and shuttled back into *E. coli* to create pTYGS·arg·*citS*·*mrl1*·S<sub>122</sub>A. Transformation of *A. oryzae* M-2-3 with this plasmid yielded 11 transformants.

**8.8.2 exp. 24: construction of pTYGS·arg·*citS*·*mrl1*·D<sub>207</sub>A** (*citS*, *mrl1* with mutation of D<sub>207</sub> to A). The *mrl1* gene was amplified from *M. ruber* cDNA as two fragments using primers *mrl1*-F/*mrl1*-R-774 and *mrl1*-F-745/*mrl1*-R. The cloned two fragments were used to do yeast recombination in *S. cerevisiae* with *AscI*-cut pTYGS·arg·*citS* and shuttled back into *E. coli* to create pTYGS·arg·*citS*·*mrl1*·D<sub>207</sub>A. Transformation of *A. oryzae* M-2-3 with this plasmid yielded 23 transformants.

**8.8.3 exp. 25: construction of pTYGS·arg·*citS*·*mrl1*·H<sub>235</sub>A** (*citS*, *mrl1* with mutation of H<sub>235</sub> to A). The *mrl1* gene was amplified from *M. ruber* cDNA as two fragments using primers *mrl1*-F/*mrl1*-R-858 and *mrl1*-F-829/*mrl1*-R. The cloned two fragments were used to do yeast recombination in *S. cerevisiae* with *AscI*-cut pTYGS·arg·*citS* and shuttled back into *E. coli* to create pTYGS·arg·*citS*·*mrl1*·H<sub>235</sub>A. Transformation of *A. oryzae* M-2-3 with this plasmid yielded 19 transformants.

## 8.9 Fermentation conditions and extraction methods

### 8.9.1 *A. oryzae* NSAR1 and transformants

The *A. oryzae* NSAR1 transformants harboring pTYGS·arg·*citS* or pTYGS·arg·*citS*·*mrl1* were selected on MAM (0.2% (w/v) ammonium chloride, 0.1% (w/v) ammonium sulfate, 0.05% (w/v) potassium chloride, 0.05% (w/v) sodium chloride, 0.1% (w/v) monopotassium phosphate, 0.05% (w/v) magnesium sulfate, 0.002% (w/v) iron-(II)-sulfate heptahydrate, 2% (w/v) D(+)-glucose monohydrate, 0.15% (w/v) L-methionine, 0.01% (w/v) adenine, 2% (w/v) agar) plates. The *A. oryzae* NSAR1 transformants harboring pTYGS·arg·*citS*·*mrl1* and pTYGS·ade series vectors (pTYGS·ade·*mrl2*, pTYGS·ade·*mrl2*·*mrl4*, pTYGS·ade·*mrl2*·*mrl7*, pTYGS·ade·*mrl2*·*mrl6*, pTYGS·ade·*mrl2*·*mrl4*·*mrl7*, pTYGS·ade·*mrl2*·*mrl6*·*mrl7*, pTYGS·ade·*mrl2*·*mrl4*·*mrl6*, or pTYGS·ade·*mrl2*·*mrl4*·*mrl6*·*mrl7*) were selected on MAM plates without adenine. For extraction, the spores were collected from 5 days old growing *A. oryzae* NSAR1 or transformants strains and inoculated in each 100 mL MPM (0.2% (w/v) ammonium chloride, 0.1% (w/v) ammonium sulfate, 0.05% (w/v) potassium chloride, 0.05% (w/v) sodium chloride, 0.1% (w/v) monopotassium phosphate, 0.05% (w/v) magnesium sulfate, 0.002% (w/v) iron-(II)-sulfate heptahydrate, 2% (w/v) D(+)-maltose monohydrate, 1% (w/v) polypeptone, 0.01% (w/v) adenine, pH 5.5) liquid media contained in 500 mL Erlenmeyer flask. The spores were allowed to grow in the liquid culture for 5 days on shakers at 160 rpm at 28 °C.

The MPM fermentation broth was filtered to remove the mycelium and acidified to pH 4.0 using 37% HCl and then transferred into a separating funnel. An equal volume of ethyl acetate was added into the separating funnel and shaken vigorously. The mixture was allowed to stand to separate the



layers. After taking out the organic layer, the rest water layer was extracted with equal volume ethyl acetate again. The organic phase from two extractions was dried ( $\text{MgSO}_4$ ), filtered and evaporated to dryness. The crude extract was dissolved in 2 mL HPLC grade MeOH and analysed by LC-MS.

### **8.9.2 *M. ruber* and mutants**

The wild-type *M. ruber* M7 or Mr $\Delta$ ku80 strains were grown on PDA (2.4%(w/v) potato dextrose broth, 1.5% (w/v) agar) plates for 7-10 days at 28 °C for spores production. The mutants obtained through ATMT method were selected on PDA plates with 15  $\mu\text{g}/\text{mL}$  G418. For extraction, the spores were collected from 10 days old growing Mr $\Delta$ ku80 or mutants strains and inoculated in each 100 mL PDB (2.4%(w/v) potato dextrose broth) liquid media contained in 500 mL Erlenmeyer flask. The spores were allowed to grow in the liquid culture for 10 days on shakers at 160 rpm at 28 °C. The extraction method of PDB fermentation broth was the same with MPM fermentation broth.

### **8.9.3 *A. oryzae* M-2-3 and transformants**

The *A. oryzae* M-2-3 transformants were selected on Czapek-Dox (3.5% (w/v) Czapek Dox broth, 4.68% (w/v) sodium chloride, 0.1% (w/v) ammonium sulfate, 0.05% (w/v) adenine, 0.15% (w/v) L-methionine, 1.5% (w/v) agar) plates. For extraction, the spores were collected from 5 days old growing *A. oryzae* M-2-3 or transformants strains and inoculated in each 100 mL CMP (3.5% (w/v) Czapek Dox broth, 2% (w/v) D(+)-maltose monohydrate, 1% (w/v) polypeptone) liquid media contained in 500 mL Erlenmeyer flask. The spores were allowed to grow in the liquid culture for 5 days on shakers at 160 rpm at 28 °C. The extraction method of CMP fermentation broth was the same with MPM fermentation broth.

## **8.10 Fungal transformation methods**

### **8.10.1 Transformation of *A. oryzae* NSAR1**

Plasmid DNA for fungal transformation was prepared using Fermentas Miniprep kits. *A. oryzae* NSAR1 or *A. oryzae* NSAR1 harboring pTYGS-arg-*citS*-*mrl1* strains were grown on DPY plates for 10 days. Spores washed by 4 mL sterile water were inoculated into 100 mL DPY liquid medium and cultivated for 2 day at 28 °C. Collect the mycelia on a sterile filter paper (autoclaved with a filter funnel) and wash with sterile water, then 0.8 M NaCl. Put the mycelia in a sterile falcon centrifuge tube. Add 10 mL of filter-sterilized TF buffer 1 (10 mg/mL Yatalase (Takara), 0.6 M  $(\text{NH}_4)_2\text{SO}_4$ , 50 mM maleic acid, pH 5.5) and incubate at 30 °C, 100rpm for 2 hours. Filter the protoplasting solution through a syringe with glasswool inside. Centrifuge the filtrate at 3000 rpm for 10 min. Wash the pelleted protoplasts with 15 mL TF buffer 2 (1.2 M sorbitol, 50 mM  $\text{CaCl}_2$ , 35 mM NaCl, 10 mM Tris HCl pH 7.5). Resuspend the protoplasts in TF buffer 2 to final concentration of  $2.5 \times 10^8/\text{mL}$ . Put 0.2 mL portions into Falcon tubes. Add 20  $\mu\text{L}$  plasmid DNA and place on ice for 30 min. Add 250  $\mu\text{L}$ , 250  $\mu\text{L}$  and 850  $\mu\text{L}$  TF buffer 3 (PEG 4000 (60% w/v), 50 mM  $\text{CaCl}_2$ , 10 mM Tris HCl pH 7.5), mix well gently and place at room temperature for 20 min. 10 mL soft agar (0.8% agar containing 5% NaCl) was added to the

transformation mixtures, and then poured onto MPM selection plates supplemented with sorbitol (1 M) and incubated at 28°C for 5-7 days.

### **8.10.2 Transformation of *A. oryzae* M-2-3**

Plasmid DNA for fungal transformation was prepared using Fermentas Miniprep kits. *A. oryzae* M-2-3 was grown on MEA plates for 10 days. Spores washed by 4 mL sterile water were inoculated into 100 mL GNB liquid medium (2% glucose, 1% nutrient broth number 2 (from Thermo Scientific)) and cultivated for 2 day at 28 °C. Collect the mycelia on a sterile filter paper (autoclaved with a filter funnel) under vacuum and wash with sterile water, then 0.8 M NaCl. Put the mycelia in a sterile falcon centrifuge tube. Add 10 mL of filter-sterilized protoplasting solution (20 mg/mL lysing enzyme (Sigma L1412), 10 mg/mL driselase (Sigma D9515), 0.8 M NaCl, 10 mM Na phosphate buffer pH 6) and incubate at 30 °C, 100rpm for no longer than 3 hours. Filter the protoplasting solution through a syringe with glasswool inside. Centrifuge the filtrate at 3000 rpm for 10 min. Wash the pelleted protoplasts once with 0.8 M NaCl (ca. 15 mL) and then once with Solution 1 (0.8 M NaCl, 10 mM CaCl<sub>2</sub>, 50 mM Tris HCl pH 7.5). Resuspend the protoplasts in Solution 1 to final concentration of  $2.5 \times 10^8$ /mL and add 1/5 volume of Solution 2 (PEG 4000 (60% w/v) in Solution 1 but 50 mM CaCl<sub>2</sub>). Put 0.2 mL portions into Falcon tubes. Add 20 µL plasmid DNA and place on ice for 30 min. Add 1 mL of Solution 2, mix well gently and place at room temperature for 20 min. 10 ml soft agar (0.8% agar containing 5% NaCl) was added to the transformation mixtures, and then poured onto Czapek-Dox plates supplemented with sorbitol (1 M) and incubated at 28°C for 5-7 days.

### **8.11 Transformation of *S. cerevisiae* for yeast recombination**

A single colony of *S. cerevisiae* YPH499 was inoculated into a 10 mL YPAD (1% (w/v) yeast extract, 2% (w/v) bacto-tryptone, 2% (w/v) glucose, 0.04% (w/v) adenine sulphate) starter culture and grown overnight at 28 °C with shaking at 200 rpm. The starter culture was then added to 40 mL of YPAD in a 250 mL flask and incubated at 28 °C with shaking at 200 rpm for 5 hours, after which the culture was centrifuged at 3000 g for 5 min and the supernatant discarded. The cells were washed with 25 mL sterile H<sub>2</sub>O and the centrifugation repeated, the pellet was then resuspended in 1 mL 0.1 M LiOAc and transferred to a 1.5 mL microfuge tube. The cells were then pelleted at 14500 rpm for 15 sec and the supernatant discarded, after which the cells were resuspended in 400 µL 0.1 M LiOAc. For each transformation to be performed 50 µL of the suspension was transferred to a new 1.5 mL microfuge tube and pelleted again at 14500 rpm for 15 sec and the supernatant discarded. 240 µL of PEG solution (50% (w/v) polyethylene glycol 3350), 36 µL 1 M LiOAc, 20 µL SS-DNA (Salmon Sperm DNA, 5 mg/ml in TE buffer, Rockland MB-103-0025) and up to 34 µL of DNA were added to the pelleted cells in order. Approximately 0.5 - 1 µg of each DNA fragment was added, with linear DNA fragments to be joined containing at least 30 bp overlap. Cells were resuspended in the transformation mixture by vortexing, and incubated at 30 °C for 30 min and then 42 °C for 30 min. The cells were pelleted at 6000 rpm for 15 sec then gently resuspended in 1 mL of sterile water. 200 µL aliquots were spread on SM-URA plates (0.17% (w/v) yeast nitrogen base, 0.5% (w/v) ammonium sulphate, 2% (w/v) glucose, 0.077% (w/v) complete supplement mixture minus uracil (Q-biogene), 1.5% (w/v) agar) and incubated at 28 °C for 3-4 days until colonies appeared.

**Table S2** List of primers used in this study


Name	Sequence (5'-3')
pks-1-F	GCCAACTTTGTACAAAAAAGCAGGCTCCGCATGATTGACTCAACTTCGCACTC
pks-1-R	TCTCTGGTCAACGATGACAGACACATATGCATCAGGGAATGTCTCG
pks-2-F	GCATATGTGTCTGTCATCG
pks-2-R	CGTGATGGTGGAGTTC
pks-3-F	CTGTTGCCATTTGGTTAGAGG
pks-3-R	ATCCATACCGCATTGATAGGAG
pks-4-F	TGCCAAATCTCCTATCAATGCGGTATG
pks-4-R	TGCCAACTTTGTACAAGAAAGCTGGGTTCGGTTAATCTAGAAATCCCATG
mr11-F-long	TTTCTTTCAACACAAGATCCCAAAGTCAAAATGAAAGGGCAGACAGGGGCTTC
mr11-F	TTTCTTTCAACACAAGATCCCAAAGTCAAAATGGTCCAGACGAATTTAGAGG
mr11-R	AGGTTGGCTGGTAGACGTCATATAATCATACTAGGGAGCACCCGTCTGCGTTG
mr12-F	TTTCTTTCAACACAAGATCCCAAAGTCAAAATGCCCATCTCAACCAAGTC
mr12-R	TTCATTCTATGCGTTATGAACATGTTCCCTTTACTTTACTTTGAGATTG
mr12-R-b	AGGTTGGCTGGTAGACGTCATATAATCATATTACTTTACTTTGAGATTG
mr14-F	AACAGCTACCCCGCTTGAGCAGACATCACCATGGCCGAAGCAGCAGC
mr14-R	ACGACAATGTCCATATCATCAATCATGACCCTACAACCTGCATACATC
mr14-R-b	AGGTTGGCTGGTAGACGTCATATAATCATACTACAACCTGCATACATC
mr16-F	TCGACTGACCAATTCCGCAGCTCGTCAAAGATGGCCTTTCCACCG
mr16-F-b	AACAGCTACCCCGCTTGAGCAGACATCACCATGGCCTTTCCACCG
mr16-R	AGGTTGGCTGGTAGACGTCATATAATCATACTACAGAACCAACTTG
mr17-F	GCCAACTTTGTACAAAAAAGCAGGCTCCGCATGGCCACAGTCAAGGTCATCG
mr17-R	TGCCAACTTTGTACAAGAAAGCTGGGTTCGGTTATATATGAGCACGGAGTCG
G418F	CCAACTCAACCCCATCGAACCGTAACC
G418R	ATCATCATGCAACATGCATG
pksCT-5F	GCCAACTTTGTACAAAAAAGCAGGCTCCGCGTCGACCACAGACCTACCCGATGAGC
pksCT-5R	TGGGGTTACGGTTCGATGGGGTTGAGTTGGAAACACGGCACCAACACC

pksCT-3F	TCAGACAGTACATGCATGTTGCATGATGATCGGAACCTGGAAATCTCAAC
pksCT-3R	TGCCAACTTTGTACAAGAAAGCTGGGTTCGGAAGCTTGACGGAATCTGCGGTCATAG
pksCT-VF	CTGTTGCCATTTGGTTAGAGG
pksCT-VR	CGCTTACCGCAGTAGACGA
mr11-5F	GCCAACTTTGTACAAAAAAGCAGGCTCCGCGGTACCATGCCACGCCACTTTCTG
mr11-5R	TGGGGTTACGGTTCGATGGGGTTGAGTTGGCCCATTGACTGTACTG
mr11-3F	TCAGACAGTACATGCATGTTGCATGATGATTCCGAGCGATTGATGACTG
mr11-3R	TGCCAACTTTGTACAAGAAAGCTGGGTTCGGTCTAGACTCTAACGCCCGTGACACC
mr11-VF	ATGCCACGCCACTTTCTG
mr11-VR	CGAAGCCAACGTCTGAAC
mr12-5F	GCCAACTTTGTACAAAAAAGCAGGCTCCGCGGTACCTCATTTCGCTGAAAG
mr12-5R	TGGGGTTACGGTTCGATGGGGTTGAGTTGGGCCACTTCGACTGCTCC
mr12-3F	TCAGACAGTACATGCATGTTGCATGATGATCCAACACTACCCAGCACAGCTTC
mr12-3R	TGCCAACTTTGTACAAGAAAGCTGGGTTCGGTCTAGAATAGAATGCCCATCTCAACCAAG
mr12-VF	TCATTTTCGCTGAAAG
mr12-VR	GGAAAACGATCCTGCAT
mr14-5F	GCCAACTTTGTACAAAAAAGCAGGCTCCGCTCTAGATATCAGGCAAGATTACCAGAACCA
mr14-5R	TGGGGTTACGGTTCGATGGGGTTGAGTTGGCAGGTCGGCGTCCTCAAAGA
mr14-3F	TCAGACAGTACATGCATGTTGCATGATGATCTGTCGTACATCGAGCAAGGC
mr14-3R	TGCCAACTTTGTACAAGAAAGCTGGGTTCGGAAGCTTGGGTATTCCCGCTGTCCATCA
mr14-VF	GCCAGGAGCGGTCACTCTATCT
mr14-VR	CGCCCGTTCGCAGTTTCTT
mr16-5F	GCCAACTTTGTACAAAAAAGCAGGCTCCGCGGTACCTTCTTATACGAAACGACGTACAAACG
mr16-5R	TGGGGTTACGGTTCGATGGGGTTGAGTTGGATGACGAGGGCCATGCTG
mr16-3F	TCAGACAGTACATGCATGTTGCATGATGATTCTCCGCAAGCGGGACCCAT
mr16-3R	TGCCAACTTTGTACAAGAAAGCTGGGTTCGGTCTAGACCAGCAGGAACCACGACCTA
mr16-VF	GGTACGTGCCCTTGAGGTTG
mr16-VR	GGTCTTGCGTCTGTTTCTTTA

mr17-5F	GCCAACTTTGTACAAAAAAGCAGGCTCCGCGGTACCCCATCGTTGCGACTACATCAC
mr17-5R	TGGGGTTACGGTTCGATGGGGTTGAGTTGGACTCCATACTCGTCACTATCCACC
mr17-3F	TCAGACAGTACATGCATGTTGCATGATGATACTCCTTCCGCGACGGGTAT
mr17-3R	TGCCAACTTTGTACAAGAAAGCTGGGTTCGGTCTAGAGCCAATGCGAAAGCGTATCA
mr17-VF	TGTTGCTGACGACGATGGAG
mr17-VR	TGGGATTGCTTGTAGAGTGGC
pks-3-R-7189	CCTGGGTTCGGATGCAAGAGC
pks-4-F-7250	CTGATCATTGCTCTTGCATCCGAACCCAGGGGGCGCCAAGAGATCATTGATAC
mr11-R-519	AAATCCAAGCAATCCAACCCAC
mr11-F-490	ACAGGAGCGTGGGTGGATTGCTTGGATTTGCCCAAGGCGCGAAGATGTGCGC
mr11-R-774	TCGCATCCCGTGTACATGCACG
mr11-F-745	ATTCCCACCGTGCATGTACACGGGATGCGAGCCCCCACGTGGACCTTCACCG
mr11-R-858	GTCACCATCCCCTACTACTAGTC
mr11-F-829	AGCAGGAGACTAGTAGAGTGGGATGGTGACGCCCGGGTTCGCTGAAGTACAATG


## 9. Previous Questionable Biosynthetic Proposals for Citrinin from the Literature.

**Figure S9.1** The biosynthesis of citrinin proposed by Hajjaj and coworkers.<sup>1</sup>



**Figure S9.2** Biosynthetic route to Citrinin proposed by Li and coworkers.<sup>2</sup>

N.b. *ctnB* is also incorrectly referred to as encoding an oxidoreductase in this paper.



**Figure 2.** Proposed pathway participated by the CtnB protein.

---






## 10. 3D Model of CitS Reductive Release Domain


### 10.1 Multiple Alignment

Peptide sequences for *M. ruber* CitS, *M. purpureus* CitS, *A. strictum* pks1 (MOS) and the myxalamid R-domain (4U7W) were aligned using ClustalW (standard parameters). Red boxes show conserved catalytic Y and K residues and NADPH binding region. C2551 is conserved in the PKS R-domains but not the myxalamid R-domain.




## 10.2 3D model

CitS residues 2305 - 2593 were submitted to SwissModel<sup>4</sup> and a model structure was built using the myxalamid structure 4U7W using standard parameters. Data was visualised using the software iMol.



View of R-domain active site showing the conserved residues: C2551 (sticks, rear); Y2392 (sticks, centre); and K2396 (sticks, front). Residues on loop W2316 - Q2330 removed for clarity. All other residues shown as spheres. Red spheres, NADPH binding residues.

## 11. Presumed Mechanism of CitE / mrl6



## 12. References

---

1. H. Hajjaj, A. Kläbe, M. Loret, G. Goma, P. Blanc and J. Francois, *Appl. Environ. Microb.*, 1999, **65**, 311–314.
2. Y.-P. Li, Y.-F. Pan, L.-H. Zou, Y. Xu, Z.-B. Huang and Q.-H. He, *J. Agr. Food Chem.*, 2013, **61**, 7397–7402.
3. P. C. Y. Woo, C.-W. Lam, E. W. T. Tam, K.-C. Lee, K. K. Y. Yung, C. K. F. Leung, K.-H. Sze, S. K. P. Lau and K.-Y. Yuen, *Sci. Rep.* 2014, **4**, 6728–8.
4. M. Biasini, S. Bienert, A. Waterhouse, K. Arnold, G. Studer, T. Schmidt, F. Kiefer, T. G. Cassarino, M. Bertoni, L. Bordoli, T. Schwede, *Nucleic Acids Research*, 2014, 42 (W1): W252-W258; K. Arnold, L. Bordoli, J. Kopp, and T. Schwede T., *Bioinformatics*, 2006, 22, 195-201; F. Kiefer, K. Arnold, M. Künzli, L. Bordoli and T. Schwede, *Nucleic Acids Research*. 2009, 37, D387-D392; N. Guex, M. C. Peitsch and T. Schwede, *Electrophoresis*, 2009, 30(S1), S162-S173.